Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer

Inclusion criteria

• Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing;
• Physical state is good: PS 0-2;
• Expected survival of more than 3 months;
• Aged 18-75 years old;
• Have not received systematic chemotherapy before;
• Did not receive cetuximab treatment;
• Liver, kidney and bone marrow functions are basically normal;
• The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;
• Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.

Exclusion criteria

• Patients with severe dysfunction of vital organs (heart, liver, kidney);
• Patients with other malignant tumors;
• Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);
• In the active phase of acute or chronic infectious diseases;
• People with a clear history of drug allergy or allergic constitution;
• Patients participating in other clinical trials;
• Other conditions in which the patient was considered inappropriate to participate in the study.